Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vistagen Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Vistagen Therapeutics, Inc.

VTGN

Vistagen Therapeutics, Inc.

About Vistagen Therapeutics, Inc.

Vistagen Therapeutics is a late-stage biopharmaceutical company focused on developing intranasal neurocircuitry-based therapies for mental health and neurological disorders. Its pipeline includes product candidates targeting social anxiety, depression, menopausal symptoms, mental fatigue, and cancer cachexia, utilizing non-systemic pherines with rapid-onset effects. The company aims to address unmet medical needs with innovative, safe, and targeted treatments for prevalent conditions.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Vistagen Therapeutics, Inc.

1
1
Vistagen Therapeutics, Inc. Vistagen Therapeutics Reports Increased Net Losses and Revenue Growth for December 2025 Quarter

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
Vistagen Therapeutics, Inc. Vistagen Therapeutics Reports $19.4 Million Net Loss for Quarter Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Vistagen Therapeutics, Inc. Vistagen Therapeutics Reports Revenue Growth to $244,000 Amid Increased Operating Losses

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
Vistagen Therapeutics, Inc. Vistagen Therapeutics Reports Fiscal Year Results, Highlights Pherine Pipeline Focus

Via official filing (AI summary) | 12 months ago | 0 comments

5
1
Vistagen Therapeutics, Inc. Vistagen Therapeutics Reports Increased Net Loss and Declining Revenue for December 2024 Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
Vistagen Therapeutics, Inc. Vistagen Therapeutics Reports Decline in Revenues, Surge in Operating Expenses, and Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments